News / Business
Celgene Corporation (NASDAQ:CELG) to Speak at Bank of America Securities Specialty Pharmaceuticals Conference August 7
Celegene Corpration (NASDAQ:CELG) will speak at the Bank of America Securities Speciatly Pharmaceuticals Conference on Thursday, August 7 at 8:30 am ET. A webcast of the presentation will b made available on the company’s Investor Relations website at ir.celgene.com.
Celgne Corporation is an integrated biopharmaceutical company. The Company is primarily engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory-related diseases.
The Company’s lead product is REVLIMID (lenalidomide) and THALOMID. REVLIMID was approved by the United States Food and Drug Administration (FDA), the European Commission, Swiss Agency for Therapeutic Products and Australian Therapeutic Goods Administration, for treatment in combination with dexamethasone for multiple myeloma patients who have received at least one prior therapy. THALOMID was approved by the FDA for treatment in combination with dexamethasone of patients with diagnosed multiple myeloma and is also approved for the treatment and suppression of cutaneous manifestations of erythema nodosum leprosum, an inflammatory complication of leprosy.
In March 2008, Celgene Corporation completed the acquisition of Pharmion Corporation.
Read more Business News on The Global Market Directory at:
